5/16/2022 7:32:27 AM
NRx Pharma Q1 Net Loss $13.4 Mln Or $0.21/shr Vs Loss Of $25.5 Mln, Or $0.71/shr Prior Year
5/12/2022 8:18:31 AM
NRx Announces Enrollment Of First Patient In Phase II Study Of Bipolar Depression With Sub-Acute Suicidality
4/21/2022 8:50:02 AM
NRx Files Breakthrough Therapy Designation Request For ZYESAMI In Subgroup Of Patients With Critical COVID-19
3/31/2022 8:25:47 AM
NRx:I-SPY COVID Trial Shows No Benefit With Addition Of ZYESAMI When Given By Mouth Inhalation In Ill COVID-19 Patients
3/31/2022 8:21:49 AM
NRx Pharma FY Net Loss $93.1 Mln Or $1.98/shr Vs. Loss Of $51.8 Mln Or $1.51/shr Prior Year
3/18/2022 5:12:38 AM
NRx Pharma Appoints Ira Strassberg As CFO And Treasurer
3/8/2022 10:32:59 PM
NRx Pharma Names Robert Besthof Interim CEO
2/15/2022 8:36:11 AM
NRx Pharma : US National Institutes Of Health Study Of ZYESAMI In Critical COVID-19 Cleared To Complete Full Enrollment
2/2/2022 8:00:22 PM
NRx Pharmaceuticals Announces Closing Of $25 Mln Private Placement
1/31/2022 8:00:05 AM
NRx Pharma Announces $25 Mln Private Placement Priced At Premium To Market
1/27/2022 6:54:41 AM
NRx : Scientific Evidence Shows BriLife Vaccine May Produce Effective Levels Of Neutralizing Antibody Against Omicron
1/26/2022 6:54:26 AM
NRx Receives Initial Report Of Patient Safety And Survival From Right To Try Use Of ZYESAMI